‘Sensible’ workers know the risks of bumper wage rises
Cochlear boss Dig Howitt says its wage bill hasn’t risen in line with inflation and employees understand the economics at play, as Philip Lowe issues a stern warning about big pay rises.
Cochlear
Banks push ASX to biggest fall in six weeks
Bourse at four-week low. CBA margins prompt selling of banks. Corporate Travel, Treasury Wine dives on misses. Cochlear jumps on buyback. Star rockets 14 per cent.
Journal sings Kazia anti-cancer drug’s praises
The potential of Kazia Therapeutics’ cancer-fighting drug EVT801 has been hailed in a scientific journal, as the company runs a clinical trial.
ASX ends up 1pc; miners gain as energy stocks slip
ASX closes at seven-month high. Warrego gives Beach Energy five days to match Hancock’s ‘superior’ offer, iron ore posts record monthly rise and Woodside leads energy losses.
Notable success in medical technology
Medical technology and medical devices is an advanced area of research, development and manufacturing in which Australia has a strong record.
Gathering seeks change of climate in China relations
Executives from a host of Australian and Chinese companies will meet in Canberra next week to discuss ways to use climate change to boost business ties with China.
Nation’s biggest health companies vow to cut carbon footprint
Australia’s biggest health companies are launching a range of strategies to cut carbon emissions, saying environmental goals are “inextricably linked” to healthcare.
Love Island and The Simpsons – how Cochlear will lift its profit 10pc this year
Hearing implants are becoming more mainstream, even featuring on The Simpsons and Love Island. Cochlear CEO Dig Howitt plans to ride the wave.
Medical device stocks that could soar from tailwinds
With strong tailwinds behind them, medical devices stocks are ready to reach new heights. Here’s why they’re set for healthy profits.
Cochlear takes long-term view on China
Hearing implant giant Cochlear is pressing ahead with its China’s plant despite increasing tensions between Canberra and Beijing.
Howitt beats a hasty retreat from China group
Cochlear CEO Dig Howitt couldn’t get off Australia’s new China foundation fast enough.
‘We’re looking for the next Apple’
Good design is more than just aesthetics, it goes to the core of the success.
Why Democrats need this to be the Covid election
Joe Biden does not want to talk about this: the most aggressive progressives have radical plans to transform America should they seize power in November.
ASX adds 0.8pc, Wesfarmers, Appen hit highs
CSL and Cochlear did the heavy lifting as the ASX rose 0.8pc, while several household names surged to record highs at the close.
Cochlear swings to loss on court costs and Covid
Hearing implant maker Cochlear has posted a $238.3m loss after elective surgery cancellations and US litigation expenses wiped out profits.
Cochlear earnings dive after litigation loss
As the coronavirus pandemic took hold and delayed elective surgeries, a patent infringement case judgment in the US was a major hit to hearing loss device developer Cochlear.
Rare chill for healthcare idols
Investors are faced with a difficult decision as two of the market’s favourite healthcare stocks suddenly catch cold.
Original URL: https://www.theaustralian.com.au/topics/cochlear/page/2